Nomura Holdings’s Anavex Life Sciences AVXL Stock Holding History

Nomura Holdings’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-25,000	Closed	-$223K	–	1894
2025 Q3	$223K	Hold	25,000	–	–	﹤0.01%	1764
2025 Q2	$231K	Buy	+25,000	New	+$213K	﹤0.01%	1278

Other funds holding AVXL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

NWAM LLC Mercer Island, Washington $1.74B AUM 32.48% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Summit Financial Parsippany, New Jersey $7.85B AUM 20.99% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Nomura Holdings's AVXL Position: Q1 2022 in Review

Nomura Holdings sold out of Anavex Life Sciences (AVXL) in Q1 2022, closing a stake of 22,540 shares — an estimated $391K sold.

Nomura Holdings first reported a position in AVXL in Q1 2016 and held it in 3 quarters. The position peaked at $2.69M in Q3 2021. 139 funds tracked by Wall St. Rank hold AVXL as of Q1 2022.

Nomura Holdings reported no remaining Anavex Life Sciences position as of Q1 2022 after selling out during the quarter.
Nomura Holdings sold 22,540 Anavex Life Sciences shares in Q1 2022, an estimated $391K.
Nomura Holdings first reported a position in Anavex Life Sciences in Q1 2016 and held it in 3 quarters.
Nomura Holdings's Anavex Life Sciences position peaked at $2.69M in Q3 2021.
139 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2022.

Based on Nomura Holdings's 13F filing for Q1 2022, filed 18 May 2022.